Health Care & Life Sciences » Biotechnology | Mount TAM Biotechnologies Inc.

Mount TAM Biotechnologies Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
74.30
21.50
5.40
375.50
46.10
57.60
Inventories
5.20
5.20
-
-
-
-
Other Current Assets
-
-
-
4.20
3.50
4.70
Total Current Assets
79.50
26.70
5.40
379.70
49.60
62.30
Long-Term Note Receivable
-
-
0.00
0.00
0.00
-
Other Assets
-
-
-
-
7.10
2.10
Total Assets
79.50
26.70
5.50
379.70
56.70
64.40
ST Debt & Current Portion LT Debt
-
-
125.90
17.50
693.90
Accounts Payable
25.70
66.40
-
-
-
Other Current Liabilities
-
-
660.20
602.70
927.30
Total Current Liabilities
25.70
66.40
786.20
620.20
1,621.20
Long-Term Debt
-
-
-
553.60
-
Total Liabilities
25.70
66.40
786.20
1,173.90
1,621.20
Common Equity (Total)
53.80
39.70
780.70
794.20
1,564.50
Total Shareholders' Equity
53.80
39.70
780.70
794.20
1,564.50
Total Equity
53.80
39.70
780.70
794.20
1,564.50
Liabilities & Shareholders' Equity
79.50
26.70
5.50
379.70
56.70

About Mount TAM Biotechnologies

View Profile
Address
106 Main Street
Burlington Vermont 05401
United States
Employees -
Website http://www.mounttambiotech.com
Updated 07/08/2019
Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.